Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Insider Trading Activity Boston Scientific Co. (NYSE:BSX) – EVP Sold 34,773 shares of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2017 | 02:47am CEST

Insider Trading Activity For Boston Scientific Co. (NYSE:BSX)

Michael P. Phalen , EVP of Boston Scientific Co. (NYSE:BSX) reportedly Sold 34,773 shares of the company’s stock at an average price of 26 for a total transaction amount of $904,098.00 SEC Form

Insider Trading History For Boston Scientific Co. (NYSE:BSX)

  • On 8/6/2012 Ernest Mario, Director, bought 32,000 with an average share price of $5.29 per share and the total transaction amounting to $169,280.00. View SEC Filing
  • On 11/9/2012 Nj Nicholas Jr, Director, bought 25,000 with an average share price of $5.17 per share and the total transaction amounting to $129,250.00. View SEC Filing
  • On 11/13/2012 Nj Nicholas Jr, Director, bought 20,000 with an average share price of $5.28 per share and the total transaction amounting to $105,600.00. View SEC Filing
  • On 5/6/2013 Ernest Mario, Director, bought 30,000 with an average share price of $7.76 per share and the total transaction amounting to $232,800.00. View SEC Filing
  • On 5/29/2013 Nelda J Connors, Director, sold 24,116 with an average share price of $9.17 per share and the total transaction amounting to $221,143.72. View SEC Filing
  • On 5/30/2013 Wendy Carruthers, SVP, sold 25,001 with an average share price of $9.16 per share and the total transaction amounting to $229,009.16. View SEC Filing
  • On 5/31/2013 Jeffrey B Mirviss, SVP, sold 10,941 with an average share price of $9.37 per share and the total transaction amounting to $102,517.17. View SEC Filing
  • Analyst Ratings For Boston Scientific Co. (NYSE:BSX)
    These are 4 Hold Ratings, 14 Buy Ratings .
    The current consensus rating for Boston Scientific Co. (NYSE:BSX) is Buy (Score: 2.78) with a consensus target price of $27.29 , a potential (4.25% upside)

    Analyst Ratings History For Boston Scientific Co. (NYSE:BSX)

    • On 7/7/2015 Stephens Initiated Coverage of rating Overweight with a price target of $21.00
    • On 1/4/2016 Sterne Agee CRT Boost Price Target of rating Buy with a price target of $21.00 to $22.50
    • On 2/25/2016 SunTrust Banks, Inc. Initiated Coverage of rating Buy with a price target of $21.00
    • On 3/12/2016 Deutsche Bank AG Reiterated Rating Hold
    • On 3/17/2016 Nomura Initiated Coverage of rating Buy with a price target of $22.00
    • On 3/18/2016 Longbow Research Initiated Coverage of rating Buy
    • On 3/25/2016 Bank of America Corp Reiterated Rating Buy with a price target of $23.00

    About Boston Scientific Co. (NYSE:BSX)
    Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

    Recent Trading Activity for Boston Scientific Co. (NYSE:BSX)
    Shares of Boston Scientific Co. closed the previous trading session at 26.18 up +0.21 0.81% with 12,027,348 shares trading hands.

    The post Insider Trading Activity Boston Scientific Co. (NYSE:BSX) – EVP Sold 34,773 shares of Stock appeared first on Market Exclusive.

    © Market Exclusive 2017, source Market Exclusive

    share with twitter share with LinkedIn share with facebook
    share via e-mail
    0
    Latest news on BOSTON SCIENTIFIC CORPORAT
    02:47a INSIDER TRADING ACTIVITY BOSTON SCIE : BSX) – EVP Sold 34,773 shares of St..
    02:47a INSIDER TRADING ACTIVITY BOSTON SCIE : BSX) – SVP Sold 10,250 shares of St..
    04/27 BOSTON SCIENTIFIC : sales leap 10 percent, but profit misses expectations
    04/27 BOSTON SCIENTIFIC CO. (NYSE : BSX) reported earnings of $0.29 per share missing ..
    04/27 BOSTON SCIENTIFIC : Contract award - 65-- icd-boston scientific
    04/27 BOSTON SCIENTIFIC : $26,000 Federal Contract Awarded to Boston Scientific
    04/27 BOSTON SCIENTIFIC CORPORATION (NYSE : BSX) Files An 8-K Results of Operations an..
    04/27 BOSTON SCIENTIFIC CORP : Results of Operations and Financial Condition, Financia..
    04/27 BOSTON SCIENTIFIC : profit jumps, but falls short of forecasts
    04/27 BOSTON SCIENTIFIC : Announces Results For First Quarter 2017
    More news
    Sector news : Advanced Medical Equipment & Technology - NEC
    04/24DJPHILIPS : Net Profit Leaps; Backs Full Year Guidance
    04/10DJCorrections & Amplifications -- WSJ
    03/28DJPHILIPS : to Buy Australian pharmacy Sleep Services Firm
    02/09 Infineon, Cree warn U.S. might block Wolfspeed deal
    02/02 EU probes online sales in electronics, video games, hotels
    More sector news : Advanced Medical Equipment & Technology - NEC
    News from SeekingAlpha
    04/27 Boston Scientific (BSX) Q1 2017 Results - Earnings Call Transcript
    04/27 Boston Scientific Q1 top line up 10%; earnings up 44%, revenue guidance raise..
    04/27 Boston Scientific misses by $0.01, beats on revenue
    04/26 Notable earnings before Thursday?s open
    04/25 The Return Of Medtech Scale-Building?
    Advertisement
    Financials ($)
    Sales 2017 8 774 M
    EBIT 2017 2 081 M
    Net income 2017 1 334 M
    Debt 2017 4 322 M
    Yield 2017 -
    P/E ratio 2017 27,84
    P/E ratio 2018 22,83
    EV / Sales 2017 4,54x
    EV / Sales 2018 4,13x
    Capitalization 35 552 M
    More Financials
    Chart BOSTON SCIENTIFIC CORPORAT
    Duration : Period :
    Boston Scientific Corporat Technical Analysis Chart | BSX | US1011371077 | 4-Traders
    Full-screen chart
    Technical analysis trends BOSTON SCIENTIFIC...
    Short TermMid-TermLong Term
    TrendsBullishBullishBullish
    Technical analysis
    Income Statement Evolution
    More Financials
    Consensus
    Sell
    Buy
    Mean consensus OUTPERFORM
    Number of Analysts 24
    Average target price 28,3 $
    Spread / Average Target 8,9%
    Consensus details
    EPS Revisions
    More Estimates Revisions
    Managers
    NameTitle
    Michael F. Mahoney Chairman, President & Chief Executive Officer
    Edward Mackey Executive Vice President-Operations
    Daniel J. Brennan Chief Financial Officer & Executive Vice President
    Ian Meredith Global Chief Medical Officer & Executive VP
    Nelda J. Connors Independent Director
    More about the company
    Sector and Competitors
    1st jan.Capitalization (M$)
    BOSTON SCIENTIFIC CORP..21.04%35 552
    THERMO FISHER SCIENTIF..18.14%65 728
    DANAHER CORPORATION6.51%57 598
    PHILIPS10.31%32 152
    INTUITIVE SURGICAL, IN..31.91%30 726
    ILLUMINA, INC.43.50%27 004
    More Results